Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 3, 2001, Pages 922-926

  Andes, D ^a   Stamsted, T ^a   Conklin, R ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CANDIDIASIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA ALBICANS; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA;

EID: 0035115021     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.3.922-926.2001     Document Type: Article

References (25)

1. Chemical and antigenic alterations of Candida albicans cell walls related to the action of amphotericin B sub-inhibitory doses
2. Correlation between in vitro and in vivo activity of antifungal agents against Candida species
3. Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice
4. Secular trends in nosocomial primary blood stream infections in the United States, 1980-1989
5. A pharmacologic guide to the clinical use of amphotericin B
6. Comparative study with enoxacin and netilmicin, a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance
7. Postantibiotic effect
8. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
9. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
10. International conference for the development of a consensus on the management and prevention of severe candida infections
11. Antifungal agents: Chemotherapeutic targets and immunologic strategies
12. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
13. Comparative pharmacokinetics of Sch 28191 and amphotericin B in mice, rats, dogs, and cynomologus monkeys
14. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
15. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
16. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia
17. Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations
18. Detection of amphotericin B-resistant Candida isolates in a broth-based system
19. Laboratory studies with antifungal agents: Susceptibility tests and bioassays
20. The postantibiotic effect of antifungal agents against common pathogenic yeasts
21. In vivo postantibiotic effect in a thigh infection in neutropenic mice
22. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
23. Experimental antifungal chemotherapy in granulocytopenic animal models of disseminated candidiasis: Approaches to understanding investigalional antifungal compounds for patients with neoplastic diseases
24. Hospital-acquired candidemia. The attributable mortality and excess length of stay